George C. Clark net worth and biography

George Clark Biography and Net Worth

George has over 10 years of experience in the areas of SEC reporting, accounting advisory, internal controls, and corporate finance. He joined Biohaven from KPMG, LLP where he was a Senior Manager in the Hartford Audit Practice, leading various audits for one of the firm’s largest clients. Prior to KPMG, George held positions in the finance group at The Hartford Financial Services Group, Inc. and began his career at PricewaterhouseCoopers, LLP in the Hartford Assurance and Advisory Practices. George is a graduate of the University of Connecticut where he earned Bachelor and Master of Science degrees in Accounting and is a Certified Public Accountant.

What is George C. Clark's net worth?

The estimated net worth of George C. Clark is at least $616,904.40 as of May 10th, 2022. Mr. Clark owns 4,065 shares of Biohaven Pharmaceutical stock worth more than $616,904 as of September 26th. This net worth approximation does not reflect any other assets that Mr. Clark may own. Learn More about George C. Clark's net worth.

How old is George C. Clark?

Mr. Clark is currently 38 years old. There are 6 older executives and no younger executives at Biohaven Pharmaceutical. The oldest executive at Biohaven Pharmaceutical is Dr. Elyse Stock M.D., Chief Medical Officer, who is 63 years old. Learn More on George C. Clark's age.

How do I contact George C. Clark?

The corporate mailing address for Mr. Clark and other Biohaven Pharmaceutical executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven Pharmaceutical can also be reached via phone at (203) 404-0410 and via email at [email protected] Learn More on George C. Clark's contact information.

Has George C. Clark been buying or selling shares of Biohaven Pharmaceutical?

George C. Clark has not been actively trading shares of Biohaven Pharmaceutical within the last three months. Most recently, George C. Clark sold 4,200 shares of the business's stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $141.50, for a transaction totalling $594,300.00. Following the completion of the sale, the chief accounting officer now directly owns 4,065 shares of the company's stock, valued at $575,197.50. Learn More on George C. Clark's trading history.

Who are Biohaven Pharmaceutical's active insiders?

Biohaven Pharmaceutical's insider roster includes Gregory Bailey (Director), Robert Berman (Insider), John Childs (Director), George Clark (CAO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven Pharmaceutical's active insiders.

Are insiders buying or selling shares of Biohaven Pharmaceutical?

In the last twelve months, Biohaven Pharmaceutical insiders bought shares 2 times. They purchased a total of 43,000 shares worth more than $6,239,870.00. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 146,674 shares worth more than $16,498,698.66. The most recent insider tranaction occured on August, 19th when Director Gregory Bailey bought 38,000 shares worth more than $5,625,520.00. Insiders at Biohaven Pharmaceutical own 12.4 % of the company. Learn More about insider trades at Biohaven Pharmaceutical.

Information on this page was last updated on 8/19/2022.

George C. Clark Insider Trading History at Biohaven Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2022Sell4,200$141.50$594,300.004,065View SEC Filing Icon  
1/19/2022Sell9,375$117.01$1,096,968.75View SEC Filing Icon  
12/20/2021Sell1,915$123.84$237,153.60View SEC Filing Icon  
See Full Table

George C. Clark Buying and Selling Activity at Biohaven Pharmaceutical

This chart shows George C Clark's buying and selling at Biohaven Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Biohaven Pharmaceutical Company Overview

Biohaven Pharmaceutical logo
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Read More

Today's Range

Now: $151.76
Low: $151.01
High: $152.13

50 Day Range

MA: $148.44
Low: $145.66
High: $151.76

2 Week Range

Now: $151.76
Low: $79.01
High: $152.13


3,155,500 shs

Average Volume

1,031,574 shs

Market Capitalization

$10.87 billion

P/E Ratio


Dividend Yield